BioNexus Gene Lab (NASDAQ:BGLC) Stock Jumps 7.5% – Should You Buy?

BioNexus Gene Lab Corp. (NASDAQ:BGLC)’s share price rose 7.5% during trading on Monday. The company traded as high as $0.8923 and last traded at $0.8923. 4,395 shares changed hands during trading, a decline of 34% from the average daily volume of 6,706 shares. The stock had previously closed at $0.83.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

BioNexus Gene Lab Stock Up 8.7%

The business’s 50-day moving average is $1.25 and its two-hundred day moving average is $1.88. The firm has a market capitalization of $2.61 million, a price-to-earnings ratio of -0.71 and a beta of 4.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.28 and a current ratio of 6.08.

BioNexus Gene Lab (NASDAQ:BGLC) last issued its earnings results on Friday, August 14th. The company reported ($0.12) EPS for the quarter. The firm had revenue of $0.08 million during the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative return on equity of 32.92%.

About BioNexus Gene Lab

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.